|Bid||1,405.00 x 16300|
|Ask||1,408.00 x 34600|
|Day's Range||1,392.50 - 1,442.00|
|52 Week Range||814.20 - 1,624.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 15, 2018|
|Forward Dividend & Yield||0.34 (2.41%)|
|1y Target Est||16.17|
The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million (407 million pounds) and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals (TEVA.TA), was named Hikma's chief executive officer in February. The company suffered a setback in March for its generic version of GlaxoSmithKline's (GSK.L) blockbuster lung drug Advair, after the U.S. Food and Drug Administration asked Hikma to conduct a further clinical study evaluating the drug, dashing hopes to get it to the market this year.
Hikma Pharmaceuticals Plc on Friday reaffirmed its revenue guidance for the full year, noting its generics business was performing better due to a favourable product mix, despite continued pricing pressure in the United States. The drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million and $600 million in 2018. Sigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals, was named Hikma's chief executive officer in February.
A large part of investment returns can be generated by dividend-paying stock given their role in compounding returns over time. Over the past 10 years, Hikma Pharmaceuticals PLC (LSE:HIK) hasRead More...
I am going to run you through how I calculated the intrinsic value of Hikma Pharmaceuticals PLC (LSE:HIK) using the discounted cash flow (DCF) method. Anyone interested in learning aRead More...
MADISON, Wis., April 2, 2018 /PRNewswire/ -- Today Propeller Health and peer-reviewed healthcare journal, Health Affairs, published results from a cross-sector partnership in Louisville, KY, that successfully reduced the burden of asthma. AIR Louisville, one of the largest studies of asthma conducted in a real-world setting, was a collaboration among 25 public, private and philanthropic organizations to use digital health technology to improve asthma. Partners and paper co-authors included representatives from city government such as the Mayor and agencies including Civic Innovation and Public Health, local business leaders and clinical providers, and nonprofit partner, the Institute for Healthy Air Water and Soil.
Hikma Pharmaceuticals PLC (LSE:HIK), a pharmaceuticals company based in United Kingdom, led the LSE gainers with a relatively large price hike in the past couple of weeks. As a mid-capRead More...
The company has struggled due to persistent price pressures in the U.S. market and was forced to cut revenue guidance for its generics business thrice in 2017. Hikma's problems were further compounded by a delay in the launch of its generic version of GlaxoSmithKline's (GSK.L) blockbuster lung drug Advair. The U.S. Food and Drug Administration on Monday asked Hikma to conduct a further clinical study evaluating the drug.
Hikma Pharmaceuticals Plc is expected to cut more jobs in its generics business to save costs, the Jordan-based drugmaker said on Wednesday, after reporting full-year profit and revenue largely in line with expectations. Hikma, which was forced to cut revenue guidance for its generics business three times in 2017 due to pricing pressures in the United States, has cut 200 jobs since it bought the business from Boehringer Ingelheim in 2016, CFO Khalid Nabilsi said in a call to Reuters. Nabilsi added that another 200 jobs would go as a result of the consolidation of its generics' manufacturing facilities and U.S. distribution centres.
Hikma Pharmaceuticals Plc reported lower-than-expected full-year core earnings on Wednesday, hurt by weakness in its generic drugs business. The Jordan-based drugmaker said earnings before interest, tax, ...
The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.
Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S. The Jordan-based firm said its expects to submit a response to the FDA with new clinical data in 2019, and hopes to start patient enrolment for the study in the coming weeks.
Hikma said its current chairman and CEO, Said Darwazah, would become executive chairman. Shares of Hikma rose as much as 5 percent in early trading on the London Stock Exchange. Olafsson's appointment comes at a time when Hikma is facing higher price erosion levels than the rest of the industry that prompted it to lower the revenue guidance for its generics business twice last year.
Serabi Gold and Dixons Carphone are two of the stocks I have identified as undervalued. This means their current share prices are trading at levels less than what the companiesRead More...
MADISON, Wis., Feb. 8, 2018 /PRNewswire/ -- Propeller Health, the leading digital solution for respiratory medicine, has been awarded International Organization for Standardization (ISO) 13485:2016 certification for medical device quality management systems. Propeller's FDA-cleared medical devices include sensors that attach to inhalers and mobile apps powered by a robust analytics platform helping patients better manage their asthma and COPD symptoms. This ISO certification is another milestone for Propeller following the company's recently announced partnership with the largest pharmacy benefit management organization in the U.S., Express Scripts, and expansion of work with GlaxoSmithKline.
GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division. The Swiss drugmaker said in an emailed statement on Thursday it had received a so-called complete response letter from the U.S. Food and Drug Administration (FDA) and a generic Advair launch this year was now "highly unlikely".
When investors think of dividend stocks, pharmaceutical and biotech companies aren’t usually front of mind. Even though drugs are relatively non-cyclical, these stocks are subjected to high regulatory risks. Yet,Read More...
German drugmaker Dermapharm is preparing for an initial public offering (IPO), probably stealing a march on much larger Siemens' (SIEGn.DE) healthcare unit Healthineers as the first stock market flotation in Germany this year. Dermapharm, which makes generic drugs, cosmetics, dietary products and medical devices, said on Monday it aimed to raise about 100 million euros ($122 million) in fresh capital to fund growth during an IPO in the first half of 2018. The family owners will also sell shares, and after the IPO 25 percent of the company will be in the hands of public investors, Dermapharm said.
Stocks with market capitalization between $2B and $10B, such as Hikma Pharmaceuticals PLC (LSE:HIK) with a size of £2.60B, do not attract as much attention from the investing community asRead More...